Mercy Daka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mercy Daka has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Donald M. Arnold
Department of Medicine, McMaster University, Hamilton, Canada
4 shared publications - Ishac Nazy
McMaster University, Hamilton, Ontario, Canada
4 shared publications - John Greenhow Kelton
Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
4 shared publications Rumi Clare
McMaster University, Hamilton, Ontario, Canada
3 shared publicationsAngela Huynh
Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
2 shared publications- Anna-Lise Bissola
McMaster University, Hamilton, Canada
2 shared publications
Latest Publications
- 3 April 2026
- Published by American Society of Hematology in Blood
Engineering single-chain variable fragments to identify pathogenic antibodies in heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is characterized by the production of pathogenic antibodies that bind to complexes of platelet factor 4 (PF4) and heparin, causing platelet activation and a hypercoagulable state. A significant proportion of heparin-treated patients develop non-pathogenic anti-PF4/heparin antibodies that do not activate platelets but interfere with routine screening tests causing frequent false-positive results. We recently showed that pathogenic HIT antibodies are monoclonal and bind to an overlapping PF4 binding site, which could be exploited to identify clinically significant antibodies in patients. This study aimed to develop epitope-specific inhibitors based on the HIT-like monoclonal antibody (KKO) that recognizes a binding site overlapping with pathogenic HIT patient antibodies on PF4. We developed a wildtype single-chain variable fragment (scFv) derived from KKO and performed site-directed mutagenesis to create a library of mutant anti-PF4/heparin scFv sequences. Five candidate scFvs were selected based on sequence enrichment following phage biopanning. We confirmed high nanomolar affinity and specific binding of these scFv fragments to PF4/heparin complexes using anti-PF4/heparin enzyme immunoassays (EIAs) and biolayer-interferometry (BLI) and demonstrated that KKO and all scFvs bind to an overlapping heparin-dependent epitope on PF4. Using patient sera, we demonstrated that our scFv candidates selectively inhibit the binding of pathogenic anti-PF4/heparin HIT antibodies and prevented platelet-activation of some samples in the serotonin release assay (SRA). Importantly, the binding of non-pathogenic antibodies to PF4/heparin was unperturbed. These findings support the use of scFvs targeting a shared pathogenic region on PF4 to improve the diagnostic accuracy of anti-PF4/heparin EIAs for HIT.
- 3 April 2026
- Published by American Society of Hematology in Blood
Engineering single-chain variable fragments to identify pathogenic antibodies in heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is characterized by the production of pathogenic antibodies that bind to complexes of platelet factor 4 (PF4) and heparin, causing platelet activation and a hypercoagulable state. A significant proportion of heparin-treated patients develop non-pathogenic anti-PF4/heparin antibodies that do not activate platelets but interfere with routine screening tests causing frequent false-positive results. We recently showed that pathogenic HIT antibodies are monoclonal and bind to an overlapping PF4 binding site, which could be exploited to identify clinically significant antibodies in patients. This study aimed to develop epitope-specific inhibitors based on the HIT-like monoclonal antibody (KKO) that recognizes a binding site overlapping with pathogenic HIT patient antibodies on PF4. We developed a wildtype single-chain variable fragment (scFv) derived from KKO and performed site-directed mutagenesis to create a library of mutant anti-PF4/heparin scFv sequences. Five candidate scFvs were selected based on sequence enrichment following phage biopanning. We confirmed high nanomolar affinity and specific binding of these scFv fragments to PF4/heparin complexes using anti-PF4/heparin enzyme immunoassays (EIAs) and biolayer-interferometry (BLI) and demonstrated that KKO and all scFvs bind to an overlapping heparin-dependent epitope on PF4. Using patient sera, we demonstrated that our scFv candidates selectively inhibit the binding of pathogenic anti-PF4/heparin HIT antibodies and prevented platelet-activation of some samples in the serotonin release assay (SRA). Importantly, the binding of non-pathogenic antibodies to PF4/heparin was unperturbed. These findings support the use of scFvs targeting a shared pathogenic region on PF4 to improve the diagnostic accuracy of anti-PF4/heparin EIAs for HIT.
- Open Access
- 24 January 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (2) , 246-250
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S
- 24 January 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (2) , 246-250
Open AccessCharacteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S
- Open Access
- 20 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (14) , 4228-4235
The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious adverse syndrome occurring 5 to 30 days after adenoviral vector COVID-19 vaccination. Therefore, a practical evaluation of clinical assessments and laboratory testing for VITT is needed to prevent significant adverse outcomes as the global use of adenoviral vector vaccines continues. We received the clinical information and blood samples of 156 patients in Canada with a suspected diagnosis of VITT between April and July 2021. The performance characteristics of various diagnostic laboratory tests were evaluated against the platelet factor 4 (PF4)-14C-serotonin release assay (SRA) including a commercial anti-PF4/heparin immunoglobulin G (IgG)/IgA/IgM enzyme immunoassay (EIA, PF4 Enhanced; Immucor), in-house IgG-specific anti-PF4 and anti-PF4/heparin-EIAs, the standard SRA, and the PF4/heparin-SRA. Of those, 43 (27.6%) had serologically confirmed VITT-positive based on a positive PF4-SRA result and 113 (72.4%) were VITT-negative. The commercial anti-PF4/heparin EIA, the in-house anti-PF4-EIA, and anti-PF4/heparin-EIA were positive for all 43 VITT-confirmed samples (100% sensitivity) with a few false-positive results (mean specificity, 95.6%). These immunoassays had specificities of 95.6% (95% confidence interval [CI], 90.0-98.6), 96.5% (95% CI, 91.2-99.0), and 97.4% (95% CI, 92.4-99.5), respectively. Functional tests, including the standard SRA and PF4/heparin-SRA, had high specificities (100%), but poor sensitivities for VITT (16.7% [95% CI, 7.0-31.4]; and 46.2% [95% CI, 26.6-66.6], respectively). These findings suggest EIA assays that can directly detect antibodies to PF4 or PF4/heparin have excellent performance characteristics and may be useful as a diagnostic test if the F4-SRA is unavailable.
- 20 July 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (14) , 4228-4235
Open AccessThe clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious adverse syndrome occurring 5 to 30 days after adenoviral vector COVID-19 vaccination. Therefore, a practical evaluation of clinical assessments and laboratory testing for VITT is needed to prevent significant adverse outcomes as the global use of adenoviral vector vaccines continues. We received the clinical information and blood samples of 156 patients in Canada with a suspected diagnosis of VITT between April and July 2021. The performance characteristics of various diagnostic laboratory tests were evaluated against the platelet factor 4 (PF4)-14C-serotonin release assay (SRA) including a commercial anti-PF4/heparin immunoglobulin G (IgG)/IgA/IgM enzyme immunoassay (EIA, PF4 Enhanced; Immucor), in-house IgG-specific anti-PF4 and anti-PF4/heparin-EIAs, the standard SRA, and the PF4/heparin-SRA. Of those, 43 (27.6%) had serologically confirmed VITT-positive based on a positive PF4-SRA result and 113 (72.4%) were VITT-negative. The commercial anti-PF4/heparin EIA, the in-house anti-PF4-EIA, and anti-PF4/heparin-EIA were positive for all 43 VITT-confirmed samples (100% sensitivity) with a few false-positive results (mean specificity, 95.6%). These immunoassays had specificities of 95.6% (95% confidence interval [CI], 90.0-98.6), 96.5% (95% CI, 91.2-99.0), and 97.4% (95% CI, 92.4-99.5), respectively. Functional tests, including the standard SRA and PF4/heparin-SRA, had high specificities (100%), but poor sensitivities for VITT (16.7% [95% CI, 7.0-31.4]; and 46.2% [95% CI, 26.6-66.6], respectively). These findings suggest EIA assays that can directly detect antibodies to PF4 or PF4/heparin have excellent performance characteristics and may be useful as a diagnostic test if the F4-SRA is unavailable.
- Top Cited Papers
- 7 July 2021
- Published by Springer Nature in Nature
- Vol. 596 (7873) , 565-569
Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia
Vaccine-induced immune thrombotic thrombocytopaenia (VITT) is a rare adverse effect of COVID-19 adenoviral vector vaccines1,2,3. VITT resembles heparin-induced thrombocytopaenia (HIT) in that it is associated with platelet-activating antibodies against platelet factor 4 (PF4)4; however, patients with VITT develop thrombocytopaenia and thrombosis without exposure to heparin. Here we sought to determine the binding site on PF4 of antibodies from patients with VITT. Using alanine-scanning mutagenesis5, we found that the binding of anti-PF4 antibodies from patients with VITT (n = 5) was restricted to eight surface amino acids on PF4, all of which were located within the heparin-binding site, and that the binding was inhibited by heparin. By contrast, antibodies from patients with HIT (n = 10) bound to amino acids that corresponded to two different sites on PF4. Biolayer interferometry experiments also revealed that VITT anti-PF4 antibodies had a stronger binding response to PF4 and PF4–heparin complexes than did HIT anti-PF4 antibodies, albeit with similar dissociation rates. Our data indicate that VITT antibodies can mimic the effect of heparin by binding to a similar site on PF4; this allows PF4 tetramers to cluster and form immune complexes, which in turn causes Fcγ receptor IIa (FcγRIIa; also known as CD32a)-dependent platelet activation. These results provide an explanation for VITT-antibody-induced platelet activation that could contribute to thrombosis.
- 7 July 2021
- Published by Springer Nature in Nature
- Vol. 596 (7873) , 565-569
Top Cited PapersAntibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia
Vaccine-induced immune thrombotic thrombocytopaenia (VITT) is a rare adverse effect of COVID-19 adenoviral vector vaccines1,2,3. VITT resembles heparin-induced thrombocytopaenia (HIT) in that it is associated with platelet-activating antibodies against platelet factor 4 (PF4)4; however, patients with VITT develop thrombocytopaenia and thrombosis without exposure to heparin. Here we sought to determine the binding site on PF4 of antibodies from patients with VITT. Using alanine-scanning mutagenesis5, we found that the binding of anti-PF4 antibodies from patients with VITT (n = 5) was restricted to eight surface amino acids on PF4, all of which were located within the heparin-binding site, and that the binding was inhibited by heparin. By contrast, antibodies from patients with HIT (n = 10) bound to amino acids that corresponded to two different sites on PF4. Biolayer interferometry experiments also revealed that VITT anti-PF4 antibodies had a stronger binding response to PF4 and PF4–heparin complexes than did HIT anti-PF4 antibodies, albeit with similar dissociation rates. Our data indicate that VITT antibodies can mimic the effect of heparin by binding to a similar site on PF4; this allows PF4 tetramers to cluster and form immune complexes, which in turn causes Fcγ receptor IIa (FcγRIIa; also known as CD32a)-dependent platelet activation. These results provide an explanation for VITT-antibody-induced platelet activation that could contribute to thrombosis.